| Name | (2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid |
|---|---|
| Synonyms | cd 3159 |
| Description | LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR[1]. |
|---|---|
| Related Catalog | |
| Target |
PPARα PPARγ |
| In Vitro | LG100754 is a selective activator of endogenous RXR heterodimers[1]. LG100754 can also improve TNFα-mediated insulin resistance in mature adipocytes[1]. LG100754 acts as a bona fide activator of endogenous RXR:PPARγ heterodimers and regulator of insulin-dependent signaling pathways[1]. |
| In Vivo | LG100754 (100 mg/kg) completely blocks the increase in glucose levels, suggesting that LG100754 can improve insulin resistance in vivo[1]. |
| References |
| Density | 1.003g/cm3 |
|---|---|
| Boiling Point | 549.4ºC at 760 mmHg |
| Molecular Formula | C26H36O3 |
| Molecular Weight | 396.56200 |
| Flash Point | 178.5ºC |
| Exact Mass | 396.26600 |
| PSA | 46.53000 |
| LogP | 6.81480 |
| Vapour Pressure | 6.63E-13mmHg at 25°C |
| Index of Refraction | 1.526 |
| RIDADR | NONH for all modes of transport |
|---|